TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03671512

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Periodontal Structure Repair (PSR)
Description: Following local anesthesia, initial pocket preparation will be done by bur abrasion utilizing specially designed burs to plane the root surface and remove the inner lining of the pocket. Following bur abrasion, thin strips of gauze sponge are placed into the created space. After removing the gauze strips, PSR is inserted to fill the spaces beginning at the pocket bottom. The final step is placing a layer of cyanoacrylate on both the gingival margin and tooth supragingivally.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Root Planing
Description: Ultrasonics and hand instruments are used to remove any subgingival deposits on the roots. Standard instruments and standard application are used. Visual or instrument tactile inspection is used to verify the roots are hard-smooth and have been adequately cleaned.
Study: NCT05054205

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational İnterviewing
Description: The most current version of Motivational İnterviewing (MI) is described in detail in Miller and Rollnick (2013) Motivational Interviewing: Helping people to change (3rd edition). Key qualities include:~MI is a guiding style of communication, that sits between following (good listening) and directing (giving information and advice).~MI is designed to empower people to change by drawing out their own meaning, importance and capacity for change.~MI is based on a respectful and curious way of being with people that facilitates the natural process of change and honors client autonomy.
Study: NCT04069728

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Explanation with 3D printed fistula model
Description: Explanation of fistula and surgery using a 3D printed model of an anal fistula that depicts the anatomy of the anal canal, the path of the anal fistula and its relation to anatomic structures.

Intervention type: OTHER
Group type: OTHER
Intervention: Standard explanation
Description: Explanation of fistula and treatment using words, diagrams and MRI images as per consultant choice. Standard clinical care.
Study: NCT04640155

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low FODMAP Diet
Description: Patients in the low FODMAP group will schedule a telephone visit with a registered dietician. During this approximately hour-long session, patients in the low FODMAP cohort will be counselled regarding FODMAP containing foods and how to effectively remove them while maintaining a nutrition-rich diet.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Regular Diet
Description: Patients in the regular diet group will receive an educational handout discussing low fiber diet, which is standard of care for those with pouchitis symptoms.
Study: NCT03504722

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prolonged Exposure
Description: All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prolonged Exposure
Description: All veterans will receive individualized, evidence-based prolonged exposure therapy. Foa's PE protocol will be used given consensus statements indicating that exposure therapy is currently the most appropriate psychotherapy for PTSD. Study therapists are already trained clinicians through the VA's PE certification process and will receive weekly supervision for all cases from the PI, who is a national Prolonged Exposure trainer.
Study: NCT01236378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus
Description: Sirolimus, 1 mg, white, triangular tablets, daily dose, dosages of any of these medications must be stable for at least 2 weeks prior to screening and continue with no change until completion of the last PK sample collection.
Study: NCT02769312

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Theta burst stimulation
Description: Theta burst transcranial magnetic stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham stimulation
Description: Sham Theta burst transcranial magnetic stimulation
Study: NCT04818203

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Clusters of Autologous Dermal Fibroblasts
Description: Dose: 1 x 10\^7 cells/1 mL/vial

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The injection solution without clusters of autologous dermal fibroblasts
Study: NCT01742416

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ultrasound
Description: Arterial cannulation facilitated by ultrasound.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Palpation Method
Description: Arterial cannulation by palpation method.
Study: NCT00640406

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dynamic Renal Stent plus Best Medical Treatment
Description: percutaneous transluminal angioplasty of the kidney artery at index procedure followed by best medical treatment for hypertension secondary to renal artery stenosis according to local standards

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best Medical Treatment
Description: best medical treatment for hypertension secondary to renal artery stenosis according to local standards
Study: NCT00392756

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gonadotropin releasing hormone (GnRH)
Description: pulsatile GnRH is delivered to adult men (18+ yrs) via portable microinfusion pump. A small dose (30 microliters) is delivered subcutaneously every 120 minutes. The initial dose is 25 ng/Kg which is increased until normal serum testosterone levels are achieved.
Study: NCT01861353

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cranberry-lingonberry juice
Study: NCT03994731

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: For IR prophylaxis, methylprednisolone (125 mg IV) given over an infusion duration between 10 - 30 minutes, immediately prior to each infusion.
Study: NCT03186001

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Description: The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Description: The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abobotulinum toxin A
Description: The purpose of this study is to describe two safe and reproducible techniques upper face botulinum toxin injection. It will also describe the effect of both techniques on the eyebrow shape and height using quantitative, objective measurements and subjective scales
Study: NCT03042832

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LOCI
Description: Leadership development with coaching and organizational change support

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Internet Based Webinar Leadership Training
Description: Internet Based Webinar Leadership Training
Study: NCT01276808

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic navigation PCI
Description: Magnetically navigated angioplasty wire technique
Study: NCT01861353

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo juice
Description: Juice iwth similar sugar concentration as cranberry-lingonberry juice but without berry extracts
Study: NCT01556230

Intervention type: PROCEDURE
Intervention: Surgical intervention for CNFA
Description: (non-experimental) standard procedure
Study: NCT01276808

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional PCI
Description: Conventional manual angioplasty wire percutaneous coronary intervention
Study: NCT01556230

Intervention type: RADIATION
Intervention: Radiotherapy for CNFA
Description: (non-experimental) standard procedure
Study: NCT00548483

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone (Oradexon, Nederland)
Description: dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: dexamethasone (Oradexon, Nederland)
Description: dexamethasone 5mg was administered every 6 hour for 1 day in group 1 and dexamethasone 10mg was administered every 6 hour for 1 day in group 2
Study: NCT03597373

Intervention type: OTHER
Intervention: reintubation
Description: Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time

Intervention type: OTHER
Intervention: reintubation
Description: Reintubation was defied by the reinstitution of invasive mechanical ventilation following extubation at any time
Study: NCT02806362

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ombitasvir/paritaprevir/ritonavir
Description: Tablet
Study: NCT03337438

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Feedback Intervention with Values
Description: The PFI with values will include information commonly included in personalized feedback interventions for alcohol use, such as norms information and drinking profile, as well as feedback on three of the assessed values that are highly important to the participant.

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Feedback Intervention Traditional
Description: This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.

Intervention type: OTHER
Group type: OTHER
Intervention: Personalized Feedback Intervention Traditional
Description: This PFI will include information on drinking profile, norms, behavioral strategies used while drinking, and practical costs related to drinking reframed as monetary values and caloric values.
Study: NCT03099902

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function
Description: Spirometry test

Intervention type: DIAGNOSTIC_TEST
Intervention: Lung function
Description: Spirometry test

Intervention type: DIAGNOSTIC_TEST
Intervention: White blood cell DNA extraction
Description: GSTP1 and TNFa polymorphisms with PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: White blood cell DNA extraction
Description: GSTP1 and TNFa polymorphisms with PCR

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary testing
Description: Urinary nicotine and cotinine detection
Study: NCT01829997

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: nanOss Bioactive 3D BVF
Description: nanOss Bioactive 3D BVF, combined with autograft and bone marrow aspirate, used in the posterolateral spine between L2 and S1. Instrumentation is required. Interbody fusion with PEEK device and autograft may or may not be performed.
Study: NCT03099902

Intervention type: DIAGNOSTIC_TEST
Intervention: Urinary testing
Description: Urinary nicotine and cotinine detection
Study: NCT02003677

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Faster-acting insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin aspart
Description: Subjects - in a euglycaemic clamp setting - will receive a single dose. The trial products will be administered subcutaneously (s.c. under the skin).
Study: NCT02514681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Study: NCT01994707

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Remote ischemic preconditioning
Description: Blood pressure cuff inflation
Study: NCT02514681

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pertuzumab

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vinorelbine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinorelbine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study: NCT01627015

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified infant follow-on formula
Description: The modified infant follow-on formula has a different carbohydrate pattern than the standard formula
Study: NCT01994707

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Deflated cuff on arm for 30 minutes.
Study: NCT01960062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Diabetes software and device
Description: USB cord, CD-rom, and application to allow communication with provider
Study: NCT02776540

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: there is 2 groups one group will receive 900 mg Clopidogrel and the other will receive 600 mg Clopidogrel

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin
Description: there's another group will receive 400 mg Aspirin
Study: NCT00408551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: floxuridine
Description: Given IV
Study: NCT01627015

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant follow-on formula
Description: Infants are fed a commercial follow-on formula
Study: NCT00186017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine/Zyprexa
Description: Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Olanzapine/Zyprexa
Description: Olanzapine was started at 2.5-10mg/day and adjusted by 2.5-5mg/day on a daily basis with a maximum dose of 20mg/day.
Study: NCT03944655

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Strepsils Anaesthetic Formula
Description: Oral administration of a Strepsils® Max Plus lozenge containing the active ingredients amylmetacresol 0.6 mg, 2,4-dichlorobenzyl alcohol 1.2 mg, lignocaine hydrochloride 10mg with sweeteners and flavourings.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Clear Mint Drops
Description: Oral administration of a lozenge containing glucose syrup, sugar, and flavourings
Study: NCT00983853

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir or matching placebo
Description: Tablet, Oral, 750 mg, q8h, 12 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telaprevir or matching placebo
Description: Tablet, Oral, 750 mg or 1125 mg, q8h, 12 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Subcutaneous injection, 180 μg, once weekly, 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a
Description: Subcutaneous injection, 180 μg, once weekly, 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (fixed dose)
Description: Tablet, Oral, 800 mg, b.i.d., 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (fixed dose)
Description: Tablet, Oral, 800 mg, b.i.d., 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (weight-based dose)
Description: Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin (weight-based dose)
Description: Tablet, Oral, 1000 mg for subjects weighing \<75 kg or 1200 mg for subjects weighing ≥75 kg, b.i.d., 48 weeks
Study: NCT03965442

Intervention type: DRUG
Intervention: Control
Description: Patients who underwent mastectomy under standard general anesthesia

Intervention type: DRUG
Intervention: Esmolol
Description: Patients who underwent mastectomy under general anesthesia with esmolol infusion
Study: NCT02081053

Intervention type: DEVICE
Group type: OTHER
Intervention: STAR™ Tumor Ablation System and StabiliT® Vertebral Augmentation System
Description: Radiofrequency targeted radiofrequency ablation (t-RFA) and targeted vertebral augmentation (RF-TVA)
Study: NCT04113070

Intervention type: DEVICE
Intervention: Anthropometric measuring
Description: To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.

Intervention type: DEVICE
Intervention: Anthropometric measuring
Description: To divide participants into overweight and obesity and non-overweight group according to their weight status, height (H), weight (W) and waist circumference (WC) will be measured with a uniform tool, which has been calibrated. When measuring the height, the subjects are required to take off their shoes and stand in an upright position. To measuring weight, the subjects are required to wear close-fitting clothes and bare feet. Subjects are required to take the standing position to measure waist circumference horizontally at the mid-point of line between the lower margin of the ribs and the upper margin of the ilium. All those data will be kept one decimal place. Anthropometric measuring will be taken at baseline and follow-up periods.

Intervention type: OTHER
Intervention: Growth environment evaluation
Description: The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.

Intervention type: OTHER
Intervention: Growth environment evaluation
Description: The information of children' growth environment, including family environment, physical activities, dietary and sleep habits, will be collected by parent-report questionnaire at baseline and follow-up periods.
Study: NCT03776305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipenem
Description: 1-h infusion of 0.5 g of imipenem diluted in 100 mL of normal saline solution, delivered via infusion pump at a constant flow rate, every 6 h. The imipenem PK studies were carried out during administration of the fourth dose of each regimen (18-24 h after the start of the regimen). Blood samples were obtained by direct venipuncture at the following times: before (time zero) and 0.25, 0.5, 0.75, 1, 2, 3, 4, 5 and 6 h after the fourth dose of each regimen.
Study: NCT01736540

Intervention type: DEVICE
Group type: OTHER
Intervention: MRI scan
Description: MRI was used to measure both liver and cardiac iron loading (R2 by FerriScan and T2\*, respectively).
Study: NCT02475512

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Wash wipes (3M)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: water and pH neutral soap
Study: NCT01458054

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)
Description: GSK2336805 and Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)
Description: GSK2336805 and Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 1 (GSK2336805 60mg x 1 dose, Omeprazole 40 mg q24h x 4 days, GSK2336805 60 mg x 1 dose and Omeprazole 40 mg x 1 dose)
Description: GSK2336805 and Omeprazole

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Description: GSK2336805 and Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Description: GSK2336805 and Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Description: GSK2336805 and Ritonavir

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cohort 2 (GSK2336805 30mg x 1 dose, Ritonavir 100mg q12h x 4 days, and Ritonavir 100mg q12h x 1 dose)
Description: GSK2336805 and Ritonavir
Study: NCT00897793

Intervention type: PROCEDURE
Intervention: venipuncture
Description: Venipuncture for blood samples. Samples will be tested for TGF-beta.

Intervention type: RADIATION
Intervention: radiation therapy
Description: Radiation treatments vary according to type of cancer and by patient per doctors' recommendation
Study: NCT01370655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-7145
Study: NCT00408551

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan hydrochloride
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given IV